SCHEMBL9974692

SCHEMBL9974692

COC(=O)c1cn(Cc2ccccc2)c(=O)c2ccc(-c3cc(C(=O)NC4CC4)ccc3C)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.51
TRIM24 O15164 1/20 0.51
BRD1 O95696 1/20 0.51
CCL2 P13500 1/20 0.51
TAF1 P21675 1/20 0.51
BRD2 P25440 1/20 0.51
SMARCA2 P51531 1/20 0.51
SMARCA4 P51532 1/20 0.51
BRPF1 P55201 1/20 0.51
EP300 Q09472 1/20 0.51
BPTF Q12830 1/20 0.51
CACNA1C Q13936 1/20 0.51
BRD3 Q15059 1/20 0.51
BRDT Q58F21 1/20 0.51
ATAD2 Q6PL18 1/20 0.51
PBRM1 Q86U86 1/20 0.51
TAF1L Q8IZX4 1/20 0.51
CREBBP Q92793 1/20 0.51
KAT2A Q92830 1/20 0.51
KAT2B Q92831 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2414021 0.93 BRD4 (0.54) BRD4TRIM24BRD1CCL2TAF1
SCHEMBL12284388 0.92 MAPK14 (0.50) BRD4MAPK14SGK1RIPK2KIT
SCHEMBL2423153 0.89 MAPK14 (0.50) BRD4TRIM24BRD1CCL2TAF1
SCHEMBL9974727 0.87 MAPK14 (0.60) MAPK14SGK1RIPK2KITKDR
SCHEMBL2418823 0.87 MAPK14 (0.53) BRD4TRIM24BRD1CCL2TAF1
SCHEMBL2416903 0.86 MAPK14 (0.49) BRD4TRIM24BRD1CCL2TAF1
SCHEMBL2420675 0.86 MAPK14 (0.50) BRD4TRIM24BRD1CCL2TAF1
SCHEMBL2422113 0.85 CACNA1G (0.49) BRD4TRIM24BRD1CCL2TAF1
SCHEMBL2421708 0.85 MAPK14 (0.61) BRD4TRIM24BRD1CCL2TAF1
SCHEMBL2421804 0.85 MAPK14 (0.51) BRD4MAPK14SGK1RIPK2KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144881-B1 ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA ASTRAZENECA AB (SE) 2012-06-20 EP disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008122765-A1 NEW COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 CYP3A7, UGT1A7, UGT2B7 BRD4 598/4885TRIM24 4861/4885BRD1 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.